3/30
02:17 pm
kpti
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $8.00 price target on the stock, down from $12.00.
Low
Report
Karyopharm Therapeutics (KPTI) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $8.00 price target on the stock, down from $12.00.
3/26
07:02 am
kpti
Karyopharm: Putting The Phase 3 Trial In Context [Seeking Alpha]
Low
Report
Karyopharm: Putting The Phase 3 Trial In Context [Seeking Alpha]
3/25
08:26 am
kpti
Karyopharm Therapeutics (KPTI) had its price target lowered by Robert W. Baird from $21.00 to $15.00. They now have an "outperform" rating on the stock.
Low
Report
Karyopharm Therapeutics (KPTI) had its price target lowered by Robert W. Baird from $21.00 to $15.00. They now have an "outperform" rating on the stock.
3/25
08:03 am
kpti
Karyopharm Therapeutics (KPTI) had its price target lowered by HC Wainwright from $15.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Karyopharm Therapeutics (KPTI) had its price target lowered by HC Wainwright from $15.00 to $8.00. They now have a "buy" rating on the stock.
3/24
08:03 pm
kpti
Karyopharm myeloma drug yields mixed data in myelofibrosis trial [Yahoo! Finance]
Medium
Report
Karyopharm myeloma drug yields mixed data in myelofibrosis trial [Yahoo! Finance]
3/24
02:58 pm
kpti
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript [Seeking Alpha]
Medium
Report
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript [Seeking Alpha]
3/24
07:58 am
kpti
Karyopharm Therapeutics jumps 18%, raises $30M privately [Seeking Alpha]
Medium
Report
Karyopharm Therapeutics jumps 18%, raises $30M privately [Seeking Alpha]
3/24
07:23 am
kpti
Karyopharm Announces $30 Million Private Placement with RA Capital [TheStreet.com]
High
Report
Karyopharm Announces $30 Million Private Placement with RA Capital [TheStreet.com]
3/24
07:16 am
kpti
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction [Yahoo! Finance]
High
Report
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction [Yahoo! Finance]
3/24
07:01 am
kpti
Karyopharm Announces $30 Million Private Placement with RA Capital
High
Report
Karyopharm Announces $30 Million Private Placement with RA Capital
3/24
07:00 am
kpti
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
High
Report
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
3/22
06:39 am
kpti
How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations [Yahoo! Finance]
High
Report
How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations [Yahoo! Finance]
3/17
06:52 am
kpti
Karyopharm Therapeutics (KPTI) was upgraded by Rodman & Renshaw to "strong-buy".
Medium
Report
Karyopharm Therapeutics (KPTI) was upgraded by Rodman & Renshaw to "strong-buy".
3/9
05:01 pm
kpti
Karyopharm Therapeutics (KPTI) is now covered by Rodman & Renshaw. They set a "buy" rating on the stock.
Medium
Report
Karyopharm Therapeutics (KPTI) is now covered by Rodman & Renshaw. They set a "buy" rating on the stock.
3/2
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/18
08:13 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
2/12
02:23 pm
kpti
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
Medium
Report
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
2/12
07:54 am
kpti
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/12
07:30 am
kpti
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
High
Report
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
2/5
07:30 am
kpti
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Low
Report
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
2/5
07:00 am
kpti
Karyopharm Therapeutics (NASDAQ:KPTI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Karyopharm Therapeutics (NASDAQ:KPTI) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
2/2
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/12
07:00 am
kpti
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Medium
Report
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
1/2
04:05 pm
kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)